Pfizer CEO Sees Metsera’s Drugs Hit Market As Early As 2028 After Completing Acquisition: Report CEO Albert Bourla told Yahoo Finance that the acquisition of GLP-1 maker Metsera is part of the company's "right to win" in the obesity drug game.
Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine partnership.
Should You Forget Pfizer and Buy This Magnificent Drug Stock Instead? Pfizer has a huge dividend yield and a high payout ratio compared to Merck, which could make Merck the more attractive dividend stock.
Why Metsera's Share Price Is Plummeting This Week The biotech start-up's stock had been rising rapidly in 2025.
Novo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In India Novo Nordisk shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc.
Where Will Pfizer Be in 3 Years? Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.
Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market? Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs.
Shutdown Deal Breathes New Life Into Wall Street The prospect of a quick end to the US government shutdown has rekindled investor confidence. Tech rebounds, semiconductors sprint ahead, and insurers feel political pressure building. Meanwhile, all eyes shift toward the last major earnings report of the season: Nvidia.
Metsera Tumbles After The Pfizer-Novo Buyout Battle Ends At $10 Billion The final bid, at $10 billion, is expected to wrap up after Nov. 13 with the next shareholders' vote.
Monday's pre-market session: top gainers and losers The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Novo Nordisk Loses Metsera Bidding War To Pfizer — But Retail Traders Aren’t Losing Faith Novo investors on Stocktwits praised new CEO Mike Doustdar as “dynamic,” saying they remain confident in Novo’s long-term obesity and diabetes pipeline despite short-term setbacks.
Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard."
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned.
Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal Delaware court denies Pfizer bid to block Metsera's Novo Nordisk deal as FTC flags antitrust risks and Pfizer prepares a higher counteroffer.
Novo Nordisk Reportedly Refrains From Backing Down In Metsera Acquisition Battle, Sweetens Bid Further According to an FT report, Pfizer now has two days to match Novo’s new bid or let its agreed-upon deal with Metsera fall through.
'It's Getting Ugly,' Analyst Says As Pfizer Escalates Its Gloves-Off Fight For Metsera Metsera stock surged Thursday on reports Pfizer has matched Novo Nordisk's $10 billion bid to buy the obesity-focused biotech.
Novo Nordisk Snaps 11-Day Losing Streak After Court Rejects Pfizer’s Challenge To $10B Metsera Deal Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera.
